6-Month GLP-1 Check-In: What Realistic Results Actually Look Like

By Dr. Farhan Abdullah, DO | Medical Director, Magnolia Functional Wellness | Southlake, TX

A patient sat down across from me last week, six months into her semaglutide protocol, and the first thing she said was, "I think it's working, but I expected to look like the before-and-after photos by now." She'd lost 24 pounds. Her blood pressure was down, her knees had stopped barking at her on the stairs, and her most recent A1c had quietly slipped out of the prediabetic range. By every measure that actually matters, she was winning. She just didn't feel like it, because the yardstick she'd been using came from a stranger's transformation video, not from her own body.

That conversation happens in my office almost every week. I'm Dr. Farhan Abdullah, and at Magnolia Functional Wellness in Southlake, the six-month mark is one of the most important checkpoints in a GLP-1 weight-loss plan. It's long enough that the medication has had a real chance to work, and early enough that we can still steer. The problem is that most people walk into that visit with expectations shaped by marketing and social media rather than by data. So let's reset the yardstick. Here's what realistic results actually look like at six months, what the research says, and how I read the numbers when a patient is sitting in front of me.

What the Scale Should Actually Show at Six Months

Let's start with the number everyone fixates on. In the STEP 1 trial, a 68-week randomized controlled study published in the New England Journal of Medicine in 2021 by Wilding and colleagues, adults on once-weekly semaglutide 2.4 mg lost an average of 14.9% of their body weight, compared with 2.4% on placebo, and 86% of the treatment group hit at least 5% loss (STEP 1 trial). Tirzepatide pushed the ceiling higher. In SURMOUNT-1, a 72-week trial published in the same journal in 2022 by Jastreboff and colleagues, average weight loss ran 15.0% at the 5 mg dose, 19.5% at 10 mg, and 20.9% at 15 mg (SURMOUNT-1 trial).

Now read those numbers carefully, because here's the part the highlight reels skip. Those figures are the result of roughly 16 to 17 months on the medication, not six. At the six-month mark, you're somewhere in the middle of that curve, not at the end of it. A useful real-world checkpoint comes from the STEP 4 trial, published in JAMA in 2021 by Rubino and colleagues, where participants completed a 20-week run-in on semaglutide before being randomized. By that 20-week point, which is right around the five-month mark, the average weight loss was 10.6% (STEP 4 trial). So if you're six months in and you've lost somewhere in the neighborhood of 8 to 14% of your starting weight, you are not behind. You are exactly where the science says you should be.

What does that translate to in pounds? For a patient who started at 220, six-month loss in the realistic range lands around 18 to 30 pounds. That's a meaningful, health-changing amount of weight. It's also, I'll be honest, not the dramatic number some people picture when they start. Part of my job at the six-month visit is helping patients see that 22 pounds gone is a genuine clinical win, not a disappointment. The patients who struggle most aren't the ones losing slowly. They're the ones measuring a real result against an imaginary one.

Why Your Curve Isn't a Straight Line

Here's something I wish every patient understood before they ever picked up their first pen. Weight loss on a GLP-1 is not linear, and it was never going to be. The trial protocols build in months of dose escalation on purpose. You don't start at the full dose. You climb to it slowly, often over four or five months, because that's how we keep nausea and GI side effects tolerable. Which means for a good chunk of your first six months, you haven't even been on a fully therapeutic dose yet.

So the shape of a normal curve looks like this. The first few weeks often bring a quick drop, partly water, partly the appetite suppression hitting hard. Then things slow. Then you bump up a dose and the scale moves again. Then it stalls for two or three weeks while your body recalibrates. Patients see that flat stretch and panic. They text my office convinced the medication "stopped working." It didn't. A plateau lasting a few weeks in month four or five is one of the most normal things I see. It's not failure. It's physiology catching its breath.

Individual variation is the other piece. In every one of these trials, the average tells you almost nothing about the individual. Some people in STEP 1 lost over 20%. Some lost almost nothing. The same medication, the same dose, wildly different responses, because metabolism, genetics, sleep, stress, baseline insulin resistance, and a dozen other factors all get a vote. When I look at a patient's six-month data, I'm not comparing them to the trial average. I'm comparing them to themselves at week one and asking whether the trend line is pointed in the right direction. If it is, we stay the course. If it's genuinely flat after we've reached a full dose, that's when we start investigating: Is the dose right? Is something in the protocol off? Are they actually taking it consistently? Is sleep apnea or a thyroid issue working against us in the background?

The Numbers That Matter More Than the Scale

If the scale were the only thing I cared about at six months, I'd be doing my patients a disservice. Some of the most important results of GLP-1 therapy never show up on a bathroom scale at all.

Start with the metabolic labs. At six months, I want a fasting glucose, an A1c, a full lipid panel, and a comprehensive metabolic panel. I see A1c values drift down out of the prediabetic range constantly on these medications. I see triglycerides fall, blood pressure ease off, and liver enzymes improve in patients who had early fatty liver changes. Those shifts lower someone's risk of a heart attack, a stroke, or a diabetes diagnosis years down the road. That's the actual point of the treatment. The smaller waistband is the bonus, not the goal.

Body composition is the next thing I dig into, and it's where I get genuinely cautious. When you lose weight quickly, some of what you lose is muscle, not just fat. That's true of any rapid weight loss, GLP-1s included. Losing lean mass in your 40s, 50s, and beyond is not a trivial thing. Muscle is metabolic protection, it's balance, it's the difference between aging strong and aging frail. So at the six-month visit I'm asking hard questions about protein intake and resistance training. If a patient tells me they've lost 25 pounds but haven't touched a weight and are eating maybe 50 grams of protein a day, we have work to do, even though the scale looks great. I'd rather see slightly slower loss with preserved muscle than a bigger scale number built partly out of lost strength.

Then there are the non-scale victories, and I never let a six-month visit go by without asking about them. Are you sleeping better? Are your joints quieter? Has the constant mental chatter about food, what some patients call "food noise," actually gone quiet? Can you walk the loop at Southlake Town Square without your knees filing a complaint? Are you off, or close to off, a blood pressure medication? Those answers tell me whether the treatment is changing someone's life, and they often matter more than whether the scale moved three pounds this month or four.

What Six Months Tells Us About the Next Six

The six-month checkpoint isn't just a report card. It's a planning meeting. And the single most useful thing the research has taught us about planning is what happens when people stop.

The STEP 4 trial answered that question directly. After the 20-week run-in, participants who continued semaglutide kept losing, dropping another 7.9% over the following stretch. The participants who were switched to placebo regained 6.9%. Same people, same starting point, and the only variable was whether the medication continued. That finding reframes the whole conversation. A GLP-1 is not a 90-day cleanse. It's treatment for a chronic, relapsing condition, and obesity behaves like one. The body defends its old weight with real biological force, ramping up hunger hormones and dialing down metabolism. The medication counteracts that. Take it away and the biology comes roaring back.

So when a patient hits a good six-month result and asks, "How much longer do I have to do this?", I'm honest with them. For most people, this is a long-term relationship with the medication, even if the dose changes over time. That doesn't mean nobody ever comes off it. It means coming off it is a deliberate, gradual, well-supported process with a real maintenance plan behind it, not a finish line you sprint across and then forget about. The patients who do best are the ones who use these first six months to build the scaffolding, the protein habits, the strength training, the sleep, the stress management, so that whatever the long-term plan ends up being, it's standing on something solid. If you want a fuller picture of how we structure that, our guide to physician-supervised GLP-1 weight loss walks through it in detail.

When Six Months Underdelivers

Not every six-month visit is a celebration, and I want to talk about that honestly, because those patients deserve a plan rather than a shrug.

First, I separate "no loss at all" from "less than I hoped." True non-response, where someone on a full dose for several months has lost essentially nothing, is real but uncommon. When it happens, I look hard at a few things. Is the dose actually optimized, or did side effects stall the titration partway up? Is the medication being taken every week, on schedule, stored correctly? Compounded products in particular can vary, and inconsistent potency shows up as inconsistent results. Is there an untreated driver in the background, like significant sleep apnea, a thyroid problem, or a medication for something else that promotes weight gain? Sometimes the GLP-1 isn't failing. Something else is quietly working against it.

And sometimes the honest answer is that this particular molecule isn't the right fit, and switching from semaglutide to tirzepatide, or adjusting the broader plan, is the move. That's a normal part of the process, not a failure. You can read more about how the specific medications differ on our semaglutide service page. The point is that an underwhelming six-month result is information, not a verdict. It tells us to reassess and adjust, which is exactly what a six-month visit is for.

Here's the practical takeaway. Six months into a GLP-1, you're not looking for a magazine cover. You're looking for a trajectory: a scale that's trending down at a sustainable pace, labs that are moving in the right direction, muscle that's being protected, and a daily life that genuinely feels better than it did half a year ago. If that's what you've got, the treatment is doing its job, even if it never matched the highlight reel. If it's not, that's a signal to dig in and change something. Either way, that six-month conversation is meant to be a real one. At Magnolia Functional Wellness here in Southlake, that's exactly how we approach it, because the goal was never a number on a screen. It was a healthier, stronger version of the person sitting in the chair.